(v) Anti-CD20 antibodies (Rituximab): Rituximab has been historically used along with TPE in patients with auto-Abs to ADAMTS13 in TTP and with auto-Abs to complement factor H (CFH) in aHUS, which has shown very good results. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.